Endocrine therapy plus ribociclib yields overall survival advantage in HR+/HER2-negative breast cancer Presented ByDr Sara A. Hurvitz, University of California, Los Angeles, Jonsson Comprehensive Cancer Centre TrialPhase 3, MONALEESA-7 ConferenceASCO 2019 15 July, 2019 15:00
